Modulating the immune system by cell therapy, i.e. transferring cells which could replace or support the host’s disrupted parts of the immune system represents an attractive therapeutic approach to realize the dream of a patient-tailored immune therapy. Such therapy is assumed to avoid the side effects which are commonly observed with pharmacological therapies such as generalized immunosuppression being associated with globally acting immunosuppressants. The identification of immune decision processes in cell therapies will thus be potentially useful in a broad array of clinical contexts:

     Within MODICELL

·         In transplantation settings: The transfer of specifically allo-tolerized T cells will allow substituting T cell deficiency which commonly occurs after stem cell transplantation. Allo-specific tolerized T cells maintain broad anti-infectious immunocompetence without aggravating the risk of graft-versus-host disease.

·         In cancer bearing hosts: Dendritic cells with potent T cell stimulatory activity will be transferred to cancer-bearing patients to help T cells to exert anti-tumor activity and prevent tumor immune evasion.


·         Infectious diseases, in which treatment against invading micro-organisms are not satisfactory and in which specifically designed T cells upon adoptive transfer will help to achieve immunological control over the invading pathogen.

·         In autoimmune disorders, e.g multiple sclerosis or rheumatoid arthritis, in which aberrant immune reactions can be redirected to normal by adoptively transferred T cells.

Overall, the development of effective immune cell therapy will also fulfil the therapeutic dream of personalized therapy. After successful identification of biomarkers, immune cell therapies can be adapted to the individual risk of diseases and thus over- or under-treatment can be avoided.

Project Title: MODICELL

Project No.: 285875

Coordinator: Andreas Heitger

Start: 01/01/2013

Duration: 48 months


CORDIS: Project Details


The Project recieves funding from the European Union FP7-People Programme under grant agreement n° 285875

© MODICELL 2013, Webdesign by BIOLUTION